Month: August 2020

Seligson & Co Fund Management Company PlcSTOCK EXCHANGE NOTICE 11 August 2020LocalTapiola Group, currently owning 38,9 % of the Seligson & Co Fund Management Company Plc, the management company of Seligson & Co OMX Helsinki 25 Exchange Traded Fund UCITS ETF, will today send to the Finnish Financial Supervision Authority a notification regarding acquisition of majority of the shares in Seligson & Co Fund Management Company Plc. LocalTapiola has signed agreements that would raise its ownership to 93,9 % and aims to acquire 100 % of the shares of Seligson & Co Fund Management Company Plc.The planned change of ownership will not have any effect on the Seligson & Co Helsinki 25 Exchange Traded Fund or its unit holders.

Seligson & Co Rahastoyhtiö OyjPÖRSSITIEDOTE 11.8.2020Suunnitellulla omistusmuutoksella ei ole vaikutusta OMX Helsinki 25 pörssinoteerattuun rahastoon tai sen osuudenomistajiin.

Ovaro Kiinteistösijoitus Oyj                              Lehdistötiedote 11.8.2020 klo 8.30Ovaro Kiinteistösijoitus Oyj:n osavuosikatsauksen 1-6/2020 julkistaminen ja kutsu tiedotustilaisuuteenOvaro Kiinteistösijoitus Oyj julkistaa tilinpäätöstiedotteen 1-6/2020 torstaina 13.8.2020 arviolta klo 8.30.TiedotustilaisuusTiedotustilaisuus sijoittajille, analyytikoille ja tiedotusvälineille järjestetään Ravintola Agorassa Mannerheimintie 103 b 13.8.2020 klo 13.00. Osavuosikatsauksen esittelee toimitusjohtaja Marko Huttunen.Tiedotustilaisuuden esitysmateriaali on nähtävillä tilaisuuden jälkeen osoitteessa www.ovaro.fi.Ovaro Kiinteistösijoitus OyjLisätiedot: Toimitusjohtaja Marko Huttunen, puh. 050 329563.Jakelu: Nasdaq Helsinki, keskeiset tiedotusvälineet ja www.ovaro.fi

Steve Muehler, the Founder & Senior Managing Member of Private Placement Markets, today announced that the firms Commercial Real Estate Financing Division (Private Placement Markets Loans – www.PPMLoans.com) will no longer be accepting financing applications from Mortgage Brokers, and will be focusing on growing its Correspondent Lending Operations, effective immediately. “I am excited with this change to our operations, though real estate finance only accounts for ten-percent of our overall business portfolio of services, it generally accounts for about ninety-percent of the firms problems, and this change will significantly change this.” According to Steve Muehler, the Correspondent Channel will feature all loan programs detailed at www.PPMLoans.com and www.EquityLockCommercial.com, and will allow Correspondents to Originate, Close...

MARSEILLE, France, Aug. 11, 2020 (GLOBE NEWSWIRE) — Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the Company has obtained funding of €6.8M under the PSPC-COVID call for projects to support the Company’s COVID-19 research and development activities. This initiative is operated on behalf of the State by Bpifrance as part of the Programme d’investissements d’avenir (PIA), led by the Secrétariat général pour l’investissement (SGPI). PSPC-COVID is a program established by the French government at the beginning of the pandemic to support the development of therapeutic solutions with a preventative or curative aim for COVID-19. Its objective is to finance research and development work, including Phase I or Phase II clinical trials carried out with French academic...

Pratteln, Switzerland, August 11, 2020 – Santhera Pharmaceuticals (SIX: SANN) announces that it has issued 600,000 reserve shares. The number of shares recorded in the commercial register has been increased to 14,195,072 shares.On August 10, 2020, 600,000 shares were issued out of the existing authorized capital as treasury shares. Santhera expects to use these shares for purposes of its financing arrangements. The new shares will be listed as per August 11, 2020.About SantheraSanthera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular and pulmonary diseases with high unmet medical need. Santhera is building a Duchenne muscular dystrophy (DMD) product portfolio to treat patients irrespective of causative mutations, disease...

Pratteln, Schweiz, 11. August 2020 – Santhera Pharmaceuticals (SIX: SANN) gibt die Ausgabe von 600’000 Vorratsaktien bekannt. Die Anzahl der im Handelsregister eingetragenen Aktien beträgt neu 14’195’072 Aktien.Am 10. August 2020 wurden aus dem genehmigten Kapital 600’000 neue eigene Aktien geschaffen. Santhera erwartet, diese Aktien für ihre Finanzierungsvereinbarungen zu verwenden. Die neuen Aktien werden per 11. August 2020 kotiert.Über SantheraSanthera Pharmaceuticals (SIX: SANN), ein Schweizer Spezialitätenpharmaunternehmen, ist auf die Entwicklung und Vermarktung innovativer Medikamente für seltene neuromuskuläre und pulmonale Erkrankungen mit hohem medizinischem Bedarf fokussiert. Santhera baut ein Duchenne-Muskeldystrophie (DMD) Produktportfolio zur Behandlung von Patienten unabhängig von ursächlichen Mutationen,...

eQ PLC HALF YEAR FINANCIAL REPORT11 August 2020 at 8:00 AMeQ PLC’S HALF YEAR REPORT 2020 – eQ IMPROVED ITS RESULT DESPITE THE CHALLENGING MARKET SITUATION – OPERATING PROFIT GREW BY 7%January to June 2020 in brief  During the period under review, the Group’s net revenue totalled EUR 23.9 million (EUR 22.9 million from 1 Jan. to 30 June 2019). The Group’s net fee and commission income was EUR 24.3 million (EUR 22.5 million).The Group’s net investment income from own investment operations was EUR -0.4 million (EUR 0.4 million), including the return from private equity funds and liquid fixed income funds.The Group’s operating profit grew by 7% to EUR 11.7 million (EUR 11.0 million).The Group’s profit was EUR 9.4 million (EUR 8.8 million).The consolidated earnings per share were EUR 0.24 (EUR 0.23).The net cash flow from the Group’s...

eQ OYJ PUOLIVUOSIKATSAUS11.8.2020, klo 8:00eQ OYJ:N PUOLIVUOSIKATSAUS 2020 – eQ PARANSI TULOSTAAN HAASTAVASTA MARKKINATILANTEESTA HUOLIMATTA – LIIKETULOS KASVOI 7%  Tammi-kesäkuu 2020 lyhyestiKonsernin nettoliikevaihto oli katsauskaudella 23,9 miljoonaa euroa (22,9 M€ 1.1.-30.6.2019).Konsernin nettopalkkiotuotot olivat 24,3 miljoonaa euroa (22,5 M€).Konsernin oman sijoitustoiminnan nettotuotot olivat -0,4 miljoonaa euroa (0,4 M€) sisältäen tuotot pääomarahastosijoituksista ja likvideistä korkorahastoista.Konsernin liikevoitto kasvoi 7 prosenttia ja oli 11,7 miljoonaa euroa (11,0 M€).Konsernin tulos oli 9,4 miljoonaa euroa (8,8 M€).Konsernin osakekohtainen tulos oli 0,24 euroa (0,23 euroa).Konsernin oman pääomarahastosijoitustoiminnan nettokassavirta oli -0,2 miljoonaa euroa (0,3 M€).Varainhoito-segmentin nettoliikevaihto kasvoi 9 prosenttia...

Schlieren/Switzerland, 11 August 2020The news release can be downloaded from the following link:AttachmentRelease